Legend Biotech Corporation (LEGN) Stock Forecast
LEGN analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.85 / 5 from 13 analysts
- Price target
- $45.62 average of analyst targets
- Upside to target
- +146.9% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $0.01
- 52-week range
- $16.65 – $36.28
LEGN analyst ratings
13 analystsNumber of analysts at each rating.
LEGN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LEGN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.01 | $0.01 | $0.01 | −$0.22 | +104.6% | 1 |
| Current fiscal year (2026) | −$0.01 | −$0.01 | −$0.01 | −$1.60 | +99.4% | 1 |
| Next fiscal year (2027) | $0.68 | $0.32 | $1.05 | −$0.01 | +6,508.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LEGN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $359.9M | $349.0M | $383.7M | +32.2% | 9 |
| Current fiscal year (2026) | $1.44B | $1.41B | $1.47B | +39.7% | 10 |
| Next fiscal year (2027) | $1.77B | $1.61B | $1.92B | +23.4% | 10 |
LEGN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LEGN revenue: reported and forecast
LEGN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.10 | $0.01 | $0.01 | $0.01 | $0.01 | −90.0% | 0 up · 0 down |
| Current fiscal year (2026) | $0.30 | −$0.01 | −$0.01 | −$0.01 | −$0.01 | −103.3% | 0 up · 0 down |
| Next fiscal year (2027) | $1.23 | $0.88 | $0.81 | $0.68 | $0.68 | −44.5% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LEGN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LEGN beat in 6 of 12.
What analysts expect from LEGN
13 analysts cover Legend Biotech; their consensus rating is buy (3.85 on a 1–5 scale, where 5 is a strong buy). The average price target is $45.62, 146.9% above the latest close of $18.48. Analysts expect earnings of −$0.01 per share for 2026, +99.4% from a year earlier. For 2027 the average estimate is $0.68 per share on revenue of $1.8 billion. Legend Biotech beat the EPS estimate in 6 of the last 12 quarters.
Related: LEGN income statement, LEGN key metrics, LEGN chart. See the LEGN stock overview for the latest quote and news.
LEGN forecast FAQ
What is Legend Biotech's price target?
The average analyst price target for Legend Biotech is $45.62, 146.9% above the latest close of $18.48.
Is Legend Biotech a buy, hold or sell?
Of 13 analysts covering Legend Biotech, 3 rate it a strong buy, 5 a buy, 5 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Legend Biotech's EPS forecast?
Analysts forecast −$0.01 per share for 2026 (range −$0.01 to −$0.01); for 2027 the estimate is $0.68.
What is Legend Biotech's revenue forecast?
The average revenue estimate for 2026 is $1.4 billion, growth of 39.7%; for 2027 it is $1.8 billion.
When does Legend Biotech report earnings?
Legend Biotech is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens; the EPS estimate is $0.01.
Does Legend Biotech usually beat earnings estimates?
Legend Biotech reported EPS at or above the analyst estimate in 6 of the last 12 quarters.